investor kindred

The Investor Relations website contains information about Kindred Biosciences, Inc.'s business for stockholders, potential investors, and financial analysts. Kindred Biosciences Inc at Cantor Virtual Global Healthcare Conference© Copyright 2012-2020 | Kindred Biosciences, Inc. | 1555 Bayshore Hwy. We launched Kindred's first fund in 2015, with a mission to create the venture firm we would have wanted to work with when we were running startups ourselves. Thursday, September 17, 2020 These statements are not promises or guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results to be materially different from any future results expressed or implied by the forward-looking statements. Track . EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA SPRINGFIELD, Mass. 07:45 CEST. These risks include, but are not limited to, the following: our limited operating history and expectations of losses for the foreseeable future; the absence of significant revenue from our products and our product candidates for the foreseeable future; the likelihood that our revenue will vary from quarter to quarter; our potential inability to obtain any necessary additional financing; our substantial dependence on the success of our products and our lead product candidates which may not be successfully commercialized even if they are approved for marketing; the effect of competition; our potential inability to obtain regulatory approval for our existing or future product candidates; our dependence on third parties to conduct some of our development activities; our dependence upon third-party manufacturers for supplies of our products and our product candidates and the potential inability of these manufacturers to deliver a sufficient  amount of supplies on a timely basis; the uncertain effect of the COVID-19 pandemic on our business, results of operations and financial condition; uncertainties regarding the outcomes of trials regarding our product candidates; our potential failure to attract and retain senior management and key scientific personnel; uncertainty about our ability to enter into satisfactory agreements with third-party licensees of our biologic products or to develop a satisfactory sales organization for our equine small molecule products; our significant costs of operating as a public company; potential cyber-attacks on our information technology systems or on our third-party providers' information technology systems, which could disrupt our operations; our potential inability to repay the secured indebtedness that we have incurred from third-party lenders, and the restrictions on our business activities that are contained in our loan agreement with these lenders; the risk that our 2020 strategic realignment plan will result in unanticipated costs or revenue shortfalls; uncertainty about the amount of royalties that we will receive from the sale of Mirataz® to Dechra Pharmaceuticals PLC; our potential inability to obtain and maintain patent protection and other intellectual property protection for our products and our product candidates; potential claims by third parties alleging our infringement of their patents and other intellectual property rights; our potential failure to comply with regulatory requirements, which are subject to change on an ongoing basis; the potential volatility of our stock price; and the significant control over our business by our principal stockholders and management. Feb. 2021. The Investor Relations website contains information about Kindred Biosciences, Inc.'s business for stockholders, potential investors, and financial analysts. Kindred aligns ambitions and achievements with the portfolio. We have a relentless focus on what founders need. Securities offered to employees pursuant to employee benefit plans Tuesday, September 15, 2020 from 3:30 PM to 3:50 PM EDT Thursday, September 17, 2020 SAN FRANCISCO, May 7, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2020 and provided updates on its programs. Statement of changes in beneficial ownership of securitiesKindred Biosciences to Participate in H.C. Wainwright Global Investment Conference, Cantor Global Healthcare Conference and Lake Street Best Ideas Growth Conference Kindred Biosciences Inc at Lake Street Best Ideas Growth ConferenceQuarterly report which provides a continuing view of a company's financial position View our term sheet. Harvard Business School Alumni Founded Companies . Suite 200 Burlingame, CA 94010 | Mirataz™ (mirtazapine transdermal ointment)